Globus Medical (NYSE:GMED) Price Target Cut to $99.00 by Analysts at Wells Fargo & Company

Globus Medical (NYSE:GMED) had its price target lowered by Wells Fargo & Company from $103.00 to $99.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage currently has an overweight rating on the medical device company’s stock.

Other equities analysts also recently issued reports about the company. BMO Capital Markets started coverage on Globus Medical in a research report on Wednesday, July 8th. They issued an “outperform” rating and a $94.00 price objective on the stock. Stifel Nicolaus lowered their price target on Globus Medical from $95.00 to $80.00 and set a “hold” rating on the stock in a report on Wednesday, July 8th. Needham & Company LLC increased their price objective on shares of Globus Medical from $114.00 to $117.00 and gave the company a “buy” rating in a report on Friday, May 8th. Weiss Ratings reissued a “hold (c+)” rating on shares of Globus Medical in a report on Monday, July 13th. Finally, UBS Group started coverage on shares of Globus Medical in a research report on Tuesday, July 28th. They set a “neutral” rating and a $82.00 target price for the company. Two analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $101.77.

Globus Medical Price Performance

GMED opened at $82.20 on Friday. The company has a 50 day simple moving average of $79.33 and a two-hundred day simple moving average of $85.23. The firm has a market cap of $11.16 billion, a P/E ratio of 21.02, a PEG ratio of 1.67 and a beta of 0.95. Globus Medical has a 1-year low of $54.15 and a 1-year high of $101.40.

Globus Medical (NYSE:GMED) last released its earnings results on Thursday, August 6th. The medical device company reported $1.34 earnings per share for the quarter, beating analysts’ consensus estimates of $1.10 by $0.24. The company had revenue of $789.61 million for the quarter, compared to analysts’ expectations of $782.88 million. Globus Medical had a net margin of 17.02% and a return on equity of 14.73%. Globus Medical’s revenue for the quarter was up 5.9% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.86 EPS. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. Equities analysts anticipate that Globus Medical will post 4.74 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director David D. Davidar sold 25,000 shares of the stock in a transaction on Friday, June 5th. The stock was sold at an average price of $80.76, for a total transaction of $2,019,000.00. Following the sale, the director owned 510,175 shares in the company, valued at approximately $41,201,733. This represents a 4.67% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 18.38% of the company’s stock.

Institutional Investors Weigh In On Globus Medical

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Annex Advisory Services LLC bought a new position in Globus Medical during the 4th quarter valued at about $20,572,000. Northwestern Mutual Wealth Management Co. lifted its stake in Globus Medical by 71,618.6% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 716,469 shares of the medical device company’s stock worth $62,555,000 after purchasing an additional 715,470 shares during the last quarter. Lecap Asset Management Ltd. bought a new stake in Globus Medical in the fourth quarter worth about $1,203,000. SG Americas Securities LLC lifted its stake in Globus Medical by 241.1% in the first quarter. SG Americas Securities LLC now owns 340,452 shares of the medical device company’s stock worth $29,333,000 after purchasing an additional 240,642 shares during the last quarter. Finally, Artemis Investment Management LLP boosted its position in shares of Globus Medical by 43.7% during the fourth quarter. Artemis Investment Management LLP now owns 738,595 shares of the medical device company’s stock valued at $64,487,000 after buying an additional 224,587 shares during the period. Hedge funds and other institutional investors own 95.16% of the company’s stock.

Key Headlines Impacting Globus Medical

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Q2 results exceeded expectations: Globus Medical reported adjusted earnings of $1.34 per share, ahead of the approximately $1.10–$1.12 consensus, while revenue reached $789.6 million versus estimates of $782.9 million. Revenue increased 5.9% year over year, and EPS rose substantially from $0.86 in the prior-year quarter. Globus Medical Q2 Earnings and Revenues Surpass Estimates
• Positive Sentiment: Profit outlook improved: Management raised its fiscal 2026 EPS guidance to $4.95–$5.05, above the prior analyst consensus of $4.74. The earnings call highlighted margin gains, spine-market growth and continued benefits from operating leverage. GMED Q2 Earnings Call Highlights
• Positive Sentiment: Analyst support remains favorable: TD Cowen maintained a Buy rating and a $115 price target, citing reaccelerating spine growth, strong earnings power and robust research-and-development investment. Globus Medical Earns Buy Rating
• Neutral Sentiment: Sales outlook was unchanged: Globus Medical kept fiscal 2026 revenue guidance near $3.2 billion, roughly in line with consensus. This limits the upside from the earnings report but indicates management is maintaining its growth expectations.
• Negative Sentiment: Some execution risks remain: Management cited risks involving Nevro and Enabling Technologies, contributing to caution around revenue growth. Wells Fargo also lowered its price target from $103 to $99, although it retained an Overweight rating. Wells Fargo Analyst Action

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.